A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer

被引：0
|
作者：
Munster, Pamela N.
Miller, Kathy
Krop, Ian E.
Dhindsa, Navreet
Reynolds, Joe
Geretti, Elena
Niyikiza, Clet
Nielsen, Ulrik
Hendriks, Bart
Wickham, Thomas J.
Moyo, Victor M.
LoRusso, Patricia
机构：
[1] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Merrimack Pharmaceut, Cambridge, MA USA
[5] Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS663
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.
    Bae, Soong June
    Yoon, Chang-Ik
    Park, So Eun
    Cha, Chi Hwan
    Kim, Dooreh
    Lee, Janghee
    Ahn, Sung Gwe
    Park, Hyung Seok
    Cho, Youngup
    Jeong, Joon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] OUTCOMES OF PATIENTS WITH HER2-POSITIVE BREAST CANCER METASTATIC TO BRAIN TREATED WITH HER2-TARGETED SYSTEMIC THERAPY AND STEREOTACTIC RADIOSURGERY
    Shumway, John
    Torras, Marina
    Reeder-Hayes, Katherine
    Jolly, Trevor
    Dees, Elizabeth
    Ray, Emily
    Muss, Hyman
    Carey, Lisa
    Shen, Colette
    NEURO-ONCOLOGY, 2021, 23 : 41 - 41
  • [43] HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
    Braso-Maristany, F.
    Griguolo, G.
    Chic, N.
    Pare Brunet, L.
    Galvan, P.
    Dieci, M. V.
    Miglietta, F.
    Giarratano, T.
    Martinez-Saez, O.
    Marin, M.
    Vidal Losada, M. J.
    Adamo, B.
    Munoz, M.
    Vivancos, A.
    Villagrasa Gonzalez, P.
    Parker, J.
    Perou, C. M.
    Conte, P. F.
    Prat, A.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S646
  • [44] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery
    Shumway, J. W.
    Torras, M.
    Hayes, K. Reeder
    Jolly, T.
    Dees, E. C.
    Ray, E. M.
    Carey, L. A.
    Shen, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E580 - E580
  • [46] Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study
    Iwase, Toshiaki
    Nithya, Sridhar
    Kai, Megumi
    Willey, Jie
    Dong, Wenli
    Shen, Yu
    Krishnamurthy, Savitri
    Lucci, Anthony
    Le-Petross, H. T. Carisa
    Nasrazadani, Azadeh
    Saleem, Sadia
    Layman, Rachel
    Valero, Vicente
    Tripathy, Debu
    Woodward, Wendy
    Cheng, Yee Chung
    Nakhlis, Faina
    Bellon, Jennifer
    Lynce, Filipa
    Ueno, Naoto
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines
    Wickham, T. J.
    Reynolds, J.
    Drummond, D. C.
    Kirpotin, D. B.
    Landenranta, J.
    Leonard, S. C.
    Geretti, E.
    Lee, H.
    Klinz, S.
    Hendriks, B. S.
    Olivier, K.
    Eckelhofer, I.
    Park, J. W.
    Benz, C. C.
    Moyo, V. M.
    Niyikiza, C.
    Nielsen, U. B.
    CANCER RESEARCH, 2010, 70
  • [48] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [49] Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
    Karlsson, Jenny
    Hagemann, Urs B.
    Cruciani, Veronique
    Schatz, Christoph A.
    Grant, Derek
    Ellingsen, Christine
    Kristian, Alexander
    Katoozi, Shirin
    Mihaylova, Dessislava
    Uran, Steinar R.
    Suominen, Mari
    Bjerke, Roger M.
    Ryan, Olav B.
    Cuthbertson, Alan
    CANCERS, 2023, 15 (13)
  • [50] Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer
    Tanioka, M.
    Parker, J. S.
    Henry, L. N.
    Tolaney, S.
    Dang, C.
    Krop, I. E.
    Harris, L.
    Polley, M.
    Berry, D. A.
    Winer, E. P.
    Carey, L. A.
    Perou, C. M.
    CANCER RESEARCH, 2019, 79 (04)
12345